Venous thromboembolism in nonagenarians

Summary

The balance between the efficacy and safety of anticoagulant therapy in patients aged ≥90 years with venous thromboembolism (VTE) is uncertain. RIETE is an ongoing, prospective registry of consecutive patients with acute, objectively confirmed, symptomatic VTE. We evaluated the efficacy and safety of anticoagulant therapy during the first three months in all patients aged ≥90 years. In addition, we tried to identify those at a higher risk for VTE. Of 21,873 patients enrolled from March 2001 to February 2008, 610 (2.8%) were aged ≥90 years. Of these, 307 (50%) presented with pulmonary embolism (PE), 240 (39%) had immobility ≥4 days, and 271 (44%) had abnormal creatinine levels. During the first three months of therapy, 140 patients aged ≥90 years (23%) died. Of these, 45 (32%) died of PE (34 of the initial episode, 11 of recurrent PE), 18 (13%) had fatal bleeding. Recent im-mobility ≥4 days was the most common risk factor for VTE (240 of 610 patients, 39%), but only 54 of them (22%) had received thromboprophylaxis. The most frequent causes for immobility were senile dementia, acute infection, trauma or decompen-sated heart failure. The duration of immobility was <4 weeks in 126 patients (52%), and most of them were bedridden at home. In conclusion, one in every four VTE patients aged ≥90 years died during the first three months of therapy. Of these, one in every three died of PE, one in every eight had fatal bleeding. Identifying at-risk patients may help to prevent some of these deaths.

Keywords

Venous thromboembolism - outcome - elderly

^* A full list of RIETE investigators is given in the Appendix.

• References

• 1 Kearon C, Kahn S, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8^th Edition).. Chest 2008; 133: 454S-545S.
• 2 Veiga F, Escriba A, Maluenda M. et al. Low-molecular-weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.. Thromb Haemost 2000; 84: 559-564.
• 3 Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly.. Clin Appl Thromb Hemost 2008; 14: 393-398.
• 4 Spencer FA, Gore JM, Lessard D. et al. Venous thromboembolism in the elderly. A community-based perspective.. Thromb Haemost 2008; 100: 780-788.
• 5 Falgà C, Capdevila JA, Soler S. et al., for the RIETE Investigators. Clinical Outcome of Patients with Venous Thromboembolism and Renal Insufficiency. Findings from the RIETE Registry.. Thromb Haemost 2007; 98: 771-776.
• 6 López-Jiménez L, Montero M, González-Fajardo JA. et al., for the RIETE investigators. Venous thromboembolism in very elderly patients: Findings from a prospective registry (RIETE).. Haematologica 2006; 91: 1046-1051.
• 7 Ruiz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, Monreal M. and the RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.. Thromb Haemost 2008; 100: 26-31.
• 8 Blanco-Molina A, Trujillo-Santos J, Criado J. et al., and the RIETE Investigators. Venous Thrombo-embolism during pregnancy or postpartum: Findings from the RIETE Registry.. Thromb Haemost 2007; 97: 186-190.
• 9 Laporte S, Mismetti P, Décousus H. et al. and the RIETE investigators. Predictive factors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism. Findings from the RIETE registry.. Circulation 2008; 117: 1711-1716.
• 10 Fang MC, Go AS, Hylek EM. et al. Age and risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.. J Am Geriatr Soc 2006; 54: 1231-1236.
• 11 Van Deelen BA, Van den Bempt PM, Egberts TC. et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation.. Drugs Aging 2005; 22: 353-360.
• 12 Vogel T, Coriol V, Kaltenbach G. et al. Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control.. Presse Med 2008; 37: 1723-1730.
• 13 Dentali F, Douketis JD, Gianni M. et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.. Ann Intern Med 2007; 146: 278-288.
• 14 Tapson VF, Decousus H, Pini M. et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.. Chest 2007; 132: 936-945.
• 15 Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.. Lancet 2008; 371: 387-394.
• 16 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8^th Edition).. Chest 2008; 133: 381S-453S.